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GlycosylationThe recent analysis of the ﬁrst successful RV144 vaccine trial revealed that a high titer of plasma anti-V2 an-
tibodies (Abs) correlated with a decreased risk of HIV-1 infection in vaccine recipients. To understand the
mechanism of immune correlates, we studied seven anti-V2 monoclonal Abs (mAbs) developed from HIV-
1 infected individuals. The V2 mAbs target conserved epitopes, including the binding site for α4β7 integrin,
and are broadly cross-reactive with various gp120 proteins. Preferential usage of the VH1-69 gene by V2
mAbs may depend on selection by the same antigenic structure. Six of seven V2 mAbs weakly neutralized
four to eight of the 41 pseudoviruses tested and resistance to neutralization was correlated with longer V2
domains. The data suggest the presence of shared, conserved structural elements in the V2 loop, and these
can be used in the design of vaccine immunogens inducing broadly reactive Abs with anti-viral activities.
© 2012 Elsevier Inc. All rights reserved.Introduction
The development of an effective HIV vaccine has remained an
enormous challenge even after 30 years of intensive research. The
ﬁrst moderate success was reported in 2009 with the RV144 clinical
vaccine trial which demonstrated a 31.2% reduction of infection in
vaccine recipients (Rerks-Ngarm et al., 2009). As vaccine-elicited an-
tibody (Ab) and CD4 T cell responses were noted without a signiﬁcant
effect on viral load, it suggested that protection was mediated by anti-
HIV-1 Abs (Tomaras and Haynes, 2010). This hypothesis was recently
conﬁrmed by data showing that vaccinees with high titers of plasma
anti-V2 Abs had signiﬁcantly lower risk of HIV-1 infection (www.
hivvaccineenterprise.org/conference/2011/webcasting) (Karasavvas
et al., 2011; Zolla-Pazner et al., 2011a). For the ﬁrst time, theCenter, 423 East 23rd Street,
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rights reserved.correlates of immunity in the RV144 trial were determined, which is
an essential step in the design of an efﬁcient HIV vaccine.
The most intriguing question is the mechanism of protection me-
diated by anti-V2 Abs and whether this is dependent on their ﬁne
speciﬁcity, titer, or immunogenetics. The V2 region is immunogenic,
inducing V2-speciﬁc Abs in approximately 20–45% of HIV-1 infected
individuals (Israel et al., 1997; Kayman et al., 1994; McKeating et al.,
1996). Cryo-electron microscopy has revealed that the V2 loop ap-
pears at the tip of the envelope (Env) trimer (White et al., 2010;
Wu et al., 2010a), and human anti-V2monoclonal Abs (mAbs) can ac-
cess the epitope as they can bind to intact virions (Nyambi et al.,
1998, 2000). Both polyclonal serum Abs and human anti-V2 mAbs
display immunologic cross-reactivity (Corti et al., 2010; Gorny et al.,
1994; Israel et al., 1997; Shotton et al., 1995) which suggests that
the V2 region contains conserved structural elements. This ﬁnding is
supported by recent studies of the sequence of the V2 loop showing
that approximately 75% of the residues, excluding the highly variable
area just downstream from the LDV/I α4β7 binding motif, are rela-
tively or strictly conserved (Zolla-Pazner and Cardozo, 2010). Map-
ping of the conformational epitope recognized by the human V2-
speciﬁc mAb 697 shows that it targets residues in V2 between
amino acids 164 and 194 (HxB2 numbering) (Gorny et al., 1994).
This segment includes two highly conserved sequences, RDK and
Table 1
Human anti-V2 mAbs developed from the cells of HIV-1-infected individuals.
# mAbs Selection Isotype Epitope Subtype of the
infecting virus
Reference
1 1361a gp140451 IgG1 k Discontinuous Bb Gorny et al.
(2000)
2 1393Aa gp140451 IgG1 k Discontinuous Bb Nyambi et al.
(2000)
3 1357a gp140451 IgG1 k Discontinuous Bb Gorny et al.
(2000)
4 697 gp120LAI IgG1λ Discontinuous B Gorny et al.
(1994)
5 830A gp120LAI IgG3 k Discontinuous B Pinter et al.
(2004)
6 2158 V1V2-gp70 IgG1 k Discontinuous B Pinter et al.
(2004)
7 2297 V1V2-gp70 IgG1 λ Discontinuous B This study
a Three mAbs were derived from the same subject; two of these mAbs (1361 and
1393A) are clonal as shown in Table 2.
b AnHIV-1 viruswas isolated from this one volunteer and classiﬁed as clade B on the basis
of the C2-V5 Env sequence; no viruses were isolated from the other four donors; the donors
were presumably infected with clade B based on their residency in the US (New York).
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the cross-reactivity of mAb 697 (Gorny et al., 1994). Structural con-
servation in the V2 region was further conﬁrmed by the identiﬁcation
of the broadly neutralizing mAbs PG9 and PG16, both of which target
a quaternary neutralizing epitope composed of portions of V2 and V3
(Walker et al., 2009). Together, the data from several sources clearly
demonstrates that there are conserved structural elements and
shared epitopes in the V2 loop (Changela et al., 2011; Spurrier et al.,
2011; Walker et al., 2009).
V2-speciﬁc mAbs have been isolated from immunized animals and
from HIV-infected humans; they display neutralizing activity with
different potency and breadth (Corti et al., 2010; He et al., 2002;
Kayman et al., 1994; McKeating et al., 1993; Pinter et al., 1998,
2004, 2005; Warrier et al., 1994; Wu et al., 1995). Monoclonal Abs
produced from immunized animals are isolate-restricted in their neu-
tralizing activity (McKeating et al., 1993); a chimpanzee mAb, C108g,
neutralized only two viruses but with high potency (Warrier et al.,
1994). The ﬁrst human V2-speciﬁc mAb, 697, was found to neutralize
two heterologous primary isolates and one pseudovirus (SF162) but
failed to neutralize HIV-1IIIB virus (Gorny et al., 1994; He et al.,
2002), while the recently developed human mAb HGP68 displayed
cross-clade neutralizing activity against few Tier 1 pseudoviruses
(Corti et al., 2010). The present study extends these previous analyses
and is the ﬁrst to characterize the immunochemical, functional and
genetic aspects of a panel of seven human V2-speciﬁc mAbsFig. 1. Conservation of the mAb 697 epitope in the V2 of pseudotyped viruses tested in the
Table 5 using http://weblogo.berkeley.edu. The logo consists of stacks of letters for each posi
at that position, while the height of letter within the stack indicates the relative frequency o
are not shown. The V2 residues in highlighted boxes are targeted by V2-speciﬁc mAb 697. T
according to their chemical properties: basic amino acids (K,R,H) are blue, acidic amino aci
acids (G,S,T,Y,C,Q,N) are green.generated in our laboratory. This characterization was undertaken
based on the hypothesis that anti-V2 Abs may contribute to protec-
tion and therefore should be a target of prophylactic vaccines.Results
Epitopes of anti-V2 mAbs
All seven anti-V2 mAbs (Table 1) were generated using standard
cellular methods (Gorny et al., 1991) based on selection of cells reac-
tive with one of the following antigens: oligomeric gp140451, recom-
binant gp120LAI or V1V2-gp70 (Gorny et al., 1994, 2000; Nyambi et
al., 2000; Pinter et al., 2004). Monoclonal Ab 2297, which is described
for the ﬁrst time in this study, was selected with V1V2-gp70.
The speciﬁcities of six V2 mAbs were compared to that of mAb 697
which was previously mapped using gp120HxB2 with one, two or
three mutated residues in an area spanning positions 168 to 194 of
the envelope region (Gorny et al., 1994). The potential epitope residues
for mAb 697 are shown on the surface of the V1V2 structure recently
described (McLellan et al., 2011) (Supplementary Fig. 1). All themutat-
ed residues which abrogated binding of mAb 697 to gp120 were found
to bewell conserved in the V2 domain of 41 pseudoviruses tested in the
TZM-bl neutralization assay. The percent of conservation of mutated
residues (yellow boxes in Fig. 1) from the N- to C-terminal side is as fol-
lows: K—90%, F—95%, Y—98%, L—76%, D—100%, P—78%, I—61%, Y—98%,
R—80% and L—98% (Fig. 1). Notably, two of the residues targeted, LD
(179/180), are part of theα4β7 integrin binding site expressed on acti-
vated T cells and are thought to be involved in the binding of virions to
these cells (Arthos et al., 2008; Nawaz et al., 2011).
The epitopes of other anti-V2 mAbs, with the exception of mAb
2297, are similar or overlapping the 697 epitope on the basis of com-
petition assays. An experiment shown in Fig. 2 indicates that ﬁve anti-
V2 mAbs (830A, 1357, 1361, 1393A and 2158), as well as unlabeled
697 serving as a positive control, inhibit the binding of biotinylated
mAb 697 to V1V2-gp70 in a dose–response manner. Inhibition by
the V2 mAbs, except 2297, was very efﬁcient at 10 μg/ml, blocking
biotinylated 697 to V1V2-gp70 in the range of 93% to 96%. In contrast,
mAb 2297 was much less competitive and inhibited only 47% of the
binding of biotinylated 697. Negative controls, mAb 447-52D (anti-
V3) and irrelevant mAb 1418 (anti-parvovirus B19) were not reactive
with V1V2-gp70 and did not compete with the V2 mAbs. In addition,
all seven V2 mAbs bound to the V1V2ZM109 scaffolded protein while
control mAbs, 654 (anti-CD4bs) and 1418 (anti-parvovirus B19)
were not reactive (Table 2). These results indicate that six of seven
V2 mAbs recognize a similar region in V2, while mAb 2297 is directed
to a different, but overlapping, epitope.neutralization assay. Sequence logo was created by alignment of 41 V2 sequences from
tion in the sequence. The overall height of the stack indicates the sequence conservation
f each amino acid at that position. The highly conserved V2 N- and C-terminal cysteines
he hypervariable region is in area spanning positions 28 to 45. Amino acids are colored
ds (D,E) are red, hydrophobic amino acids (A,V,L,I,P,W,F,M) are black and polar amino
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Fig. 2. Competition of V2mAbs with biotinylated anti-V2mAb 697 for binding to a V1V2-
gp70 fusion protein. Unlabeled V2 and control mAbs were titrated at ﬁnal concentrations
ranging from 10 to 0.01 μg/ml, while biotinylatedmAb 697was used at 0.2 μg/ml. Anti-V3
mAb 447 (447-52D) and anti-parvovirus B19 mAb 1418 were used as negative controls.
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Several studies have reported that polyclonal serum V2-speciﬁc
Abs and mAbs are cross-reactive with recombinant and solubilized
Env proteins from different viruses (Gorny et al., 1994; Israel et al.,
1997; Kayman et al., 1994). The seven anti-V2 mAbs studied here
were screened against 21 recombinant gp120 proteins from viruses
representing subtypes A, AG, B and C (Table 2). Each V2 mAb dis-
played broad cross-reactivity, reacting with 12 to 19 of the 21
gp120 molecules. The most cross-reactive was mAb 697 and the
least cross-reactive was mAb 2297. All V2 mAbs reacted with the pos-
itive controls, V1V2-gp70 and V1V2ZM109, but failed to react with the
negative control, BSA. The control mAb 654 (anti-CD4bs) reacted
with the majority of gp120s but did not bind to V1V2 fusion proteins
while the irrelevant mAb 1418 did not react with any tested antigens.Table 2
ELISA cross-reactivity of human anti-V2 mAbs with recombinant gp120 molecules
derived from viruses from clades A, B and Ca.
V2 mAbs CD4bs B19
# gp120s Subb 697 1393A 830A 2158 1357 1361 2297 654 1418
1 MN B 4.1 3.9 3.9 4.0 4.1 4.0 4.1 3.4 0.1
2 IIIB B 4.0 4.2 4.1 4.2 4.0 3.9 4.4 4.2 0.1
3 JR-FL B 4.0 4.0 3.9 3.9 4.0 3.9 4.1 3.9 0.1
4 REJO4541 B 3.9 3.8 3.8 3.9 4.0 4.0 4.0 3.8 0.1
5 C.ZA1197 C 3.7 3.7 2.4 2.6 2.3 3.4 2.4 3.5 0.1
6 DU172 C 3.6 3.8 3.7 3.8 3.7 3.8 3.7 3.7 0.1
7 TRO B 3.9 4.0 0.9 4.1 3.9 3.9 4.3 2.1 0.1
8 ZM53M C 3.3 3.6 3.5 3.4 3.3 4.0 1.4 3.5 0.1
9 ZM109 C 3.5 3.5 3.6 3.6 3.6 3.8 1.2 1.3 0.1
10 ZM233M C 3.6 3.7 3.7 1.8 1.4 3.9 0.5 3.5 0.1
11 p1058 B 3.7 3.8 3.8 3.7 3.7 3.8 3.5 0.1 0.1
12 MSC5007 4.2 3.9 4.0 3.9 4.1 nt 0.2 3.9 0.1
13 ZM197M C 3.5 3.6 3.6 3.7 3.6 4.0 0.4 3.6 0.1
14 DU422 C 3.7 3.8 3.6 3.7 0.5 3.8 0.3 3.6 0.1
15 CAP210 C 3.6 3.7 3.5 1.7 1.0 4.0 0.1 3.8 0.1
16 DU156 C 3.5 3.5 0.9 3.6 0.6 4.1 0.2 3.2 0.1
17 89.6 B 4.0 1.4 0.1 4.4 1.0 nt 4.2 0.3 0.1
18 KER2018 A 0.2 0.2 2.2 0.8 0.9 nt 0.1 3.9 0.1
19 DU151 C 3.6 1.5 0.3 0.3 0.2 3.9 0.4 0.5 0.1
20 PVO B 2.3 0.1 0.1 0.5 0.1 0.1 0.1 1.3 0.1
21 92RW020 A 0.1 0.2 1.7 0.2 0.1 nt 0.1 0.3 0.1
Controlsc
V1V2-gp70 B 3.5 3.8 3.7 3.6 3.5 4.0 3.7 0.1 0.1
gp70 − 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
V1V2ZM109 C 3.4 4.2 4.1 4.5 3.1 3.9 0.5 0.1 0.1
BSA − 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
AG
a A standard ELISA was used to determine the binding activity of seven V2 mAbs and two
control mAbs, 654 (anti-CD4bs) and 1418 (anti-parvovirus B19). Monoclonal Abs were
tested at concentration 10 μg/ml against gp120s, V1V2-gp70, V1V2ZM109 and BSA coated
onto ELISA plate at 1 μg/ml. The numbers are O.D. values, and shading shows O.D. values:
>2 (bold, dark), 0.5–2 (bold, gray); no binding b0.5 (white);
bSub—subtype of HIV-1;
cControls—include two positive controls: V1V2-gp70 fusion protein containing V1V2Case-A2
(clade B) sequence (Kayman et al., 1994) and V1V2ZM109 clade C sequence in 1FD6 scaffold
(McLellan et al., 2011), and two negative controls: gp70 protein (Kayman et al., 1994) and
bovine serum albumin (BSA); nt—not tested.Use of immunoglobulin (Ig) variable genes by anti-V2 mAbs
Previous studies by us and others show biased usage of Ig genes
and gene families by anti-V3, anti-CD4i, anti-gp41 and other mAbs
(Gorny et al., 2009; Huang et al., 2004; Scheid et al., 2009). Therefore,
the seven anti-V2 mAbs were sequenced and analyzed to determine
whether some Ig genes were similarly used in a dominant fashion
by anti-V2 mAbs. The sequence analysis revealed that two of three
mAbs, 1361 and 1393A, generated from one individual but at differ-
ent times (6 months apart), were derived from the same B cell
clone. Both mAbs use the same VH and VK genes and the CDR3 of
the heavy and light chain amino acid sequences are very similar
with three and two residue differences, respectively (Table 3). Analy-
sis of all V2 mAbs showed that only two VH family genes were used,
VH1 and VH4. Notably, the VH1-69 gene was particularly dominant,
encoding for four of six V2 mAbs targeting the 697 epitope (mAb
2297 recognized a different epitope) including the two clonal mAbs
(1361 and 1393A). Thus three of ﬁve unique mAbs used the same
gene segment. This preferential gene usage suggests that the VH1-
69 encoded mAbs may recognize the same V2 structural element.
The light chain genes were different for each V2 mAb with the excep-
tion of the clonal mAbs, 1361 and 1393A, which used the same VK3-
20 gene (Table 3).
The length of CDR H3, which is most actively involved in the inter-
action with antigens, ranged between 14 and 23 amino acids. Three
mAbs, 830A, 2297 and 2158, had unusually long CDR H3 regions of
20, 22 and 23 amino acids, respectively.
Mutations in the VH and VL genes, which reﬂect the differences in
the nucleotide sequence compared to germline, were in the range of
2.4% to 13.0% (mean 6.2%) for the VH genes, and 0.4% to 9.0% (mean
2.9%) for the VL genes (Table 3). The rate of the heavy chain mutation
is relatively low compared to broadly cross-neutralizing mAbs: 19%
and 21% for mAbs PG9 and PG16, respectively, speciﬁc to quaternary
epitopes (Walker et al., 2009) and >30% for mAbs VRC01, VRC02 and
VRC03 against CD4 binding site (Wu et al., 2010b).
Crystal structure of Fab 697's antigen-binding site
We further characterized V2 mAb 697 by crystallizing its Fab and
determining the crystal structure to 2.5 Å resolution (Fig. 3 and Sup-
plementary Fig. 2). The antigen-binding site of 697 is relatively ﬂat
and neutral in charge (Figs. 3A and B). This is very different from all
the anti-V3 mAbs we have studied, which almost always have the an-
tigen binding site negatively charged with a binding pocket (Burke et
al., 2009; Jiang et al., 2010). Optical docking area (ODA) analyzed by
molecular modeling using the software ICM (Molsoft LLC, La Jolla,
CA) (Abagyan et al., 1994) predicted that the CDR H2 and H3 loops
of the heavy chain likely play a dominant role in interaction with
the antigen (Fig. 3C). The antigen binding site consists of roughly
two distinct regions: (1) a shallow groove running across the antigen
binding site between the heavy and light chains and formed by large
aromatic residues which can accommodate residues with large side
chains, such as Tyr, in the epitope identiﬁed by previous functional
studies (Gorny et al., 1994) and (2) a convex hydrophobic surface
comprised of a cluster of CDR H2/H3 residues (Fig. 3D).
The V1V2 structure, in the context of a scaffold andmAb PG9, folds
as four anti-parallel beta strands according to recently published data
(McLellan et al., 2011) and is similar to the bridging sheet region tar-
geted by anti-CD4i antibodies. The majority of anti-CD4i mAbs are
encoded by the VH1-69 gene (Gorny et al., 2009; Huang et al.,
2004) and two of these mAbs, 412d and 17b, have been compared
with mAb 697 (Supplementary Figs. 3 and 4). The amino acid se-
quence of 697 CDR H2 is highly homologous with the corresponding
domain of 412d and 17b and, like these anti-CD4i mAbs, its hydro-
phobic residues may play a similar role in its interaction with the
V2 epitope consistent with the ODA prediction (Kwong et al., 1998)
Table 3
Immunoglobulin gene usage by human anti-V2 mAbs.
mAbs IGHV % muta CDR H3 H3 length AA IGLV % muta CDR L3
1361b 1-69 4.5 ARSRDHFFDTRVFQG 15 K3-20 1.8 QHYAGSRT
1393Ab 1-69 2.4 ARSRGHYFDTRVFEG 15 K3-20 0.4 QQYGGSRT
1357b 1-2 5.9 VRRAVLTALPPRYYFDF 17 K1-39 2.9 QQSHSTSWT
697 1-69 5.9 ATSGVGLHFGYFDY 14 L1-40 1.0 QSYDSSLSGYV
2158 1-69 8.7 ARDKSDVVVVTSIRPAYYYGMDV 23 K1-5 3.9 QQYNSSPET
830A 4-34 13.0 ARAPSGYPGVSLYQYYGLDV 20 K3-15 9.0 QQYKHWPPYT
2297 4-61 3.4 ATHSYQLAMIRGIIMKEDAFDI 22 L1-51 1.1 GTWDNSLSAGW
a Percentage of nucleotide mutations determined using the IMGT database (http://imgt.cines.fr).
b Monoclonal Abs generated from the same HIV-1 infected donor at different time points; two of these mAbs (1361 and 1393A) are derived from one B cell clone as they use the
same Ig genes and have only few different residues (bold) in the CDRs H3 and L3.
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backbones of the 697 heavy chain (excluding CDR H3) with that of
412d and 17b showed a pairwise root mean square deviation
(RMSD) of 1.02 Å and 0.67 Å, respectively, which indicate a close su-
perimposition, while light chain L1 and L2 show an RMSD of 1.4 Å and
1.7 Å, respectively, as they are encoded by different VL genes. Gener-
ally the antigen binding sites of the three Fabs have similar backbone
conformations except CDR H3 (Supplementary Fig. 3). Furthermore,
since both 412d and 17b mAbs bind to one side of a four stranded
bridging sheet (Supplementary Fig. 5), mAb 697 may use a similar
binding mode consistent with its relatively ﬂat antigen binding sur-
face (Fig. 3B).
Neutralization of pseudoviruses (psVs)
The anti-V2 mAbs were tested for their ability to neutralize a
panel of 41 cloned pseudoviruses (psVs) using the TZM-bl cellFig. 3. Structural characteristics of the antigen-binding site of mAb 697. (A) A side view of t
light chain and heavy chain are colored cyan and green, respectively, while CDR loops (Kaba
surface of the antigen-binding site viewed from the top (same view for panels C and D). No
docking area (ODA) analysis of Fab 697. This analysis uses desolvation energy to predict sit
and size of the spheres are proportional to the region's likelihood to be involved in antigen
role in antigen binding and hot spots of binding are concentrated at CDRs H2 and H3. (D) R
hydrophobic cluster of residues from CDRs H2 and H3.assay. The panel included 15 neutralization-sensitive Tier 1 psVs
(subtype A, AG, B, and C), 22 moderately resistant Tier 2 psVs (sub-
types B and C) and four resistant Tier 3 psVs (subtype B) (Table 4)
(Seaman et al., 2010). Generally, the neutralizing activity of V2
mAbs is weak and limited to neutralization-sensitive psVs. Only four
to eight Tier 1 psVs of 41 tested were neutralized by V2 mAbs with
the exception of mAb 2297 which showed no neutralizing activity.
The IC50 values which express the concentration (μg/ml) of mAb
needed to achieve 50% neutralization showed a broad range between
b0.4 and 88.7 μg/ml.
Dose–response curves for the six V2 mAbs with neutralizing activ-
ity are shown for each of the eight anti-V2 mAb-sensitive pseudo-
viruses (Fig. 4). These curves are generally parallel and overlapping
indicating, again, that the V2 mAbs recognize similar or identical epi-
topes. Monoclonal Ab 1357, from the same individual whose cells
generated the clonal mAbs 1361 and 1393A, has comparable activity
except that it does not neutralize pseudoviruses 6535.3 andhe crystal structure of Fab 697 (only the Fv region is shown). The frame regions of the
t deﬁnition) are colored individually. (B) The electrostatic potential is displayed on the
te the relatively ﬂat and hydrophobic surfaces of the antigen-binding site. (C) Optical
es of antigen–antibody interactions, and spheres are placed at the surface. The redness
–antibody interactions. ODA analysis suggested that the heavy chain plays a dominant
esidues identiﬁed by ODA analysis that may play key roles in antigen binding. Note the
Table 4
Neutralization of pseudotyped viruses by human anti-V2 mAbsa.
Virus Tier Clade 1361 1393A 2158 697 1357 830A 2297 1418
MW965.26 1A C <0.4 0.8 0.8 1.8 0.8 <0.4 >50 >50
SF162.LS 1A B 5.4 12.5 6.4 19.9 33.5 6.2 >50 >50
DJ263.8 1B A 11.8 11.1 9.1 38.6 29.2 7.7 >50 >50
BaL.26 1B B 5.8 8.6 7.3 20.2 7.9 36.1 >50 >50
Bx08.16 1B B 4.8 7.2 7.9 11.2 9.5 >50 >50 >50
SS1196.1 1B B 23.8 88.7 27.6 16.8 >100 >50 >50 >50
HXB2.DG 1B B 18.6 19.8 17.8 >100 36.9 >50 >50 >50
6535.3 1B B 12.1 18.5 >100 >100 >100 >50 >50 >50
BZ167.12 1B B >50 >100 >100 >100 >100 >50 >50 >50
HO29.12 1B B >50 >100 >100 >100 nt >50 >50 >50
ZM109F.PB4 1B C >50 >100 >100 >100 >100 >50 >50 >50
ZM197M.PB7 1B C >50 >100 >100 >100 nt >50 >50 >50
25710-2.43 1B C >50 >100 >100 >100 >100 >50 >50 >50
242-14 1B AG >50 >100 >100 >100 >100 >50 >50 >50
271-11 1B AG >50 >100 >100 >100 >100 >50 >50 >50
HO30.7 2 B >50 >100 >100 >100 nt >50 >50 >50
HO31.7 2 B >50 >100 >100 >100 nt >50 >50 >50
QH0692.42 2 B >50 >100 >100 >100 >100 >50 >50 >50
REJO4541.67 2 B >50 >100 >100 >100 nt >50 >50 >50
RHPA4259.7 2 B >50 >100 >100 >100 nt >50 >50 >50
WITO4160.33 2 B >50 >100 >100 >100 nt >50 >50 >50
SC422661.8 2 B >50 >100 >100 >100 >100 >50 >50 >50
TRO.11 2 B >50 >100 >100 >100 >100 >50 >50 >50
AC10.0.29 2 B >50 >100 >100 >100 nt >50 >50 >50
THRO4156.18 2 B >50 >100 >100 >100 nt >50 >50 >50
CAAN5342.A2 2 B >50 >100 >100 >100 nt >50 >50 >50
JRFL.JB 2 B >50 >100 >100 >100 nt >50 >50 >50
CAP45.2.00.G3 2 C >50 >100 >100 >100 nt >50 >50 >50
CAP210.2.00.E8 2 C >50 >100 >100 >100 nt >50 >50 >50
Du156.12 2 C >50 >100 >100 >100 >100 >50 >50 >50
Du172.17 2 C >50 >100 >100 >100 nt >50 >50 >50
Du422.1 2 C >50 >100 >100 >100 nt >50 >50 >50
ZM53M.PB12 2 C >50 >100 >100 >100 >100 >50 >50 >50
ZM135M.PL10   2 C >50 >100 >100 >100 >100 >50 >50 >50
ZM214M.PL15 2 C >50 >100 >100 >100 nt >50 >50 >50
ZM233M.PB6 2 C >50 >100 >100 >100 >100 >50 >50 >50
ZM249M.PL1 2 C >50 >100 >100 >100 >100 >50 >50 >50
HO35.18 3 B >50 >100 >100 >100 nt >50 >50 >50
HO61.14 3 B >50 >100 >100 >100 nt >50 >50 >50
PVO.4 3 B >50 >100 >100 >100 >100 >50 >50 >50
TRJO4551.58 3 B >50 >100 >100 >100 nt >50 >50 >50
a
Neutralization of psVs was performed using the TZM-bl cell assay with mAbs titrated frommaximum concentrations of either 50 or 100 μg/ml. The numbers above represent the IC
50values and are color-coded from the most potent (red), to medium (orange), to weak (yellow) neutralization. Monoclonal Ab 1418 was included as negative control. nt—not tested.
202 M.K. Gorny et al. / Virology 427 (2012) 198–207SS1196.1, suggesting that its epitope is slightly different (Fig. 4,
Table 4).
Length and N-linked glycosylation sites in V2 domain
The V2 sequences of all 41 tested pseudoviruses were aligned
(Table 5) to analyze the length and the presence of N-linked glycosylation
sites in order to test whether these characteristics correlated with neu-
tralization sensitivity. The V2 loops studied here are shown to vary in
length between 35 and 48 amino acids (Table 5). For the neutralization-
sensitive psVs, the V2 lengths varied between 38 and 41 amino acids,
with a mean length of 38.5. In contrast, the V2 domains of the
neutralization-resistant psVswas signiﬁcantly longer and varied between
35 and 48 amino acids, with a mean length of 41.3 (p=0.0292).
To determine the number of potential N-linked glycosylation sites
within V2, the “N-glycosite” program provided by the Los Alamos
HIV-1 Database was used (www.hiv.lanl.gov). There was an increased
number of V2 glycosylation sites in resistant psVs (2.42) compared to
sensitive psVs (1.88), however, the difference did not reach statistical
signiﬁcance (p=0.0695).
Generally, according to published studies, a longer V2 region is ac-
companied by an increased number of N-linked glycosylation sites
(Owens et al., 2007; Sagar et al., 2006; van Gils et al., 2011). As
shown in Fig. 5, there is a signiﬁcant correlation between the lengthand number of N-linked glycosylation sites in 41 psVs tested
(pb0.0001) and the sensitive viruses form a cluster with shorter
lengths and fewer glycosylation sites. The additional glycosylation
sites are included mainly in the hypervariable fragment of the V2 do-
main which is responsible for the varied length of V2 (Fig. 1, Table 5).
These results suggest that the resistance of some pseudoviruses to
neutralization by anti-V2 mAbs may depend on masking of the corre-
sponding epitopes by glycans associated with longer V2 domains. In
order to exclude the possibility that a lack of V2 epitopes in the virus en-
velope is the reason for resistance, we compared the neutralization and
binding of V2 mAbs to gp120 derived from the pseudoviruses tested in
the neutralization assay. Twelve pairs of neutralization (Table 4) and
binding data (Table 2) were analyzed and all 12 gp120s were recognized
by themajority of V2mAbs but, none of the corresponding pseudoviruses
were neutralized by these mAbs (Supplementary Table 2). It indicates
that the epitopes for the anti-V2 mAbs were present in the envelope of
the pseudoviruses but they were still resistant to neutralization, possibly
due to the masking effect of carbohydrates on the virus surface.
Discussion
The V2 region of gp120 has long been known to induce Abs in HIV-
infected individuals, but only a few human V2-speciﬁc mAbs have
been described (Corti et al., 2010; Gorny et al., 1994, 2000; He et al.,
Table 5
Sequence alignment of the V2 domain of 41 pseudotyped viruses tested in the TZM-bl
neutralization assaya.
Virus ID V2 sequence AAb N c
Tier 1 viruses sensitive to anti-V2 mAbs
MW965.26      SFNMTTELRD KKKQVYALFY KLDIVSLNEN SN---NSSE- -----YRLIN 4
DJ263.8   SFNMTTELRD KKQKVSALFY RLDVVQINES ---------- -GNSQYRLIN 39
HXB2.DGd SFNISTSIRG KVQKEYAFFY KLDIIPIDN- -----DT--- ---TSYRLTS 3
SF162.LS      SFKVTTSIRN KMQKEYALFY KLDVVPIDND --NTS----- -----YKLIN 3
Bal.26     SFNITTNIRG KVQKEYALFY ELDIVPIDN- -----KI--- ---DSYRLIS 3
Bx08.16     SFNITTSVRN KMKREYALFY SLDIVPI-DN -----DN--- ---TSYRLRS 3
SS1196.1   SFNITTNIRD KGQKEYALFY KTDVVPIDND N--------- ---TSYRMIS 3
6535.3  SFNITTNRGD KRQKEYALLY RTDIVSIENT S--------- ---SSYRLIS 3
Tier 1, 2 and 3 viruses resistant to anti-V2 mAbs
PVO.4        SFNVTTDIRD RMQKVYALFY RPDVVPIQDH TIENNNTIEN --NTTYRLIS 4
QH0692.42   SFSVPTGIKD KVQNVYALFY KLDVIPIDDN --NNSSKNNN GSYSSYRLIN 4
ZM197M.PB7   TFNITTEVRD RKTKQRALFY KLDVVPLEEE KNSSSKNSSY ---KEYRLIS 4
ZM135M.PL10a SFNVTTELTD KKKNMRALFY RADIEPLDGN SNESINSSEG ---DKYILIN 4
SC422661.8      SFNITTAIRD KVQKTYALFY RLDVVPIDNN HGNSSSN--- --YSNYRLIN 4
AC10.0.29    SFNITTNMRD KMQKQYALFY KLDVVPIEEG --KNNNSS-- --FTDYRLIS 4
RHPA4259.7   SFNVTSGIRD KVQKEYALLY KLDIVQIDND NTSHRDN--- ---TSYRLIS 4
Du172.17      SFNTTTEITD KKKKEYALFY KLDVVALDGK ETNSTNSSE- -----YRLIN 4
H061.14    SFNVSSSVRD KMKREYALFY KLDIVPIDDS --NSSSSN-- --YSSYRLIN 4
ZM109F.PB4  SFNITTDVKD RKQKVNATFY DLDIVPLS-- --SSDNSSNS ---SLYRLIS 4
25710-2.43 SFNLTTELRD KKQKVHALFY RLDIVPLNDT EKK------- NSSRPYRLIN 4
CAP45.2.00.G3 SFNITTELRD KKQKAYALFY RPDVVPLNKN SPSG------ -NSSEYILIN 4
CAP210.2.00.E8 SFNATTELRD KKKKEYALFY RLDIVPLKNE SESQN----- --FSEYILIN 4
TRO.11     SFNITAGIRD KVKKEYALFY KLDVVPIEED KDT--NK--- ---TTYRLRS 4
Du422.1       SFNTTTELRD KKQKVYALFY KPDVVPLNGG EHN------- -ETGEYILIN 4
ZM214M.PL15   SFKVNSELRD KNRREHALFY KLDIVQLNDE --GNDS---- --YS-YRLIN 4
BZ167.12 SFNITTNIRN KMQSTYALFY KLDVEPID-- --KNKNT--- ---TRYRLIS 4
242-14      SFNMTTELRD KKQKVSAFFY RQDVVPVNSN Q--------- -DNSSYRLIN 40 
WITO4160.33 SFNTTTVIRD KIQKEYALFY KLDIVPIEGK NTN------- ---TGYRLIN 4
Du156.12    SFNTTTELRD KKQKVYALFY RTDVVPLNNN N--------- -NNSEYILIN 4
ZM233M.PB6   SFNMTTELRD KKRKVNVLFY KLDLVPLT-- --NSSNTTN- -----YRLIS 4
ZM249M.PL1   SFNITTELRD KKQKVYALFY KLDILPLNGN ---------- NDSNEYRLIN 4
ZM53M.PB12   SFNATTELRD KKKQVYALFY KLDIVPLD-G RN---NSSE- -----YRLIN 4
H029.12    SFNVTASIRD KVKTEYALFY SLDVVPIEDN -----DN--- ---TSYRLRS 39
H031.7    SFNITTDMRD KVQKQHALFY SLDVVPIDNS N--------- ---NSYRLIS 3
THRO4156.18  SFNITTNVRD KVKREYALFY NLDVVKLEE- -----GE--- ---TSYRLVS 3
REJO4541.67 SFNITTTPRD KIQKEYAIFY KQDVVPIKND N--------- ---ISYRLIS 3
CAAN5342.A2  SFNTTTSMSD KMQKEYALFY TLDVVPIVK- --ENN----- ----TYRLIS 3
JRFL.JB    SFNITTSIRD EVQKEYALFY KLDVVPIDN- -----NN--- ---TSYRLIS 3
TRJO4551.58   SFNITTATGD K-KKERAFFY KLDVAPIDNS N--------- ---TSYRLIS 3
H030.7      SFNISTKIKD KAQKEYALFY KLDIAQIDNS ---------- ---TGYRLIS 3
H035.18      SFNATTGITN KMKKEYALFD RLDVIPIDN- ----SSI--- --YA---LIN 3
271-11        SFNVT-ELRN KRKKEYAFFY KQDIVQINNN ---------- ----ESMLIS 3
1 3
2
8 2
8 1
8 1
8 2
8 2
8 2
8 4
8 3
7 3
7 3
5 3
4 3
4 3
4 3
4 3
3 4
3 3
3 2
3 3
2 2
2 2
1 1
0 2
2
0 1
0 2
0 3
0 2
0 3
2
8 2
8 1
8 2
8 2
8 3
7 2
7 2
7 2
5 2
a
Alignment and potential N-linked glycosylation sites (red) were determined using
clustal X program and N-glycosite program from Los Alamos HIV-1 Database;
bNumber of amino acids (AA) in the V2 domain;
c
N—number of potential N-linked glycosylation sites;
dUnderlined residues (black) are involved in the 697 epitope.
203M.K. Gorny et al. / Virology 427 (2012) 198–2072002; Nyambi et al., 2000; Pinter et al., 2004), and only one has been
characterized in detail (Gorny et al., 1994). Therefore, the goal of this
study was to fully characterize a panel of human V2-speciﬁc mAbs in
terms of speciﬁcity, immunogenetics and function, particularly in the
context of the RV144 vaccine data which showed the protective abil-
ity of the V2 antibodies (www.hivvaccineenterprise.org/conference/
2011/webcasting).
The most interesting element of the presented studies is the immu-
nochemical and functional cross-reactivity of the V2mAbs (Table 2 and
(Corti et al., 2010; Gorny et al., 1994)) which demonstrates that these
mAbs recognize conserved immunologic features in V2, despite its se-
quence variability. A competition ELISA of a V2 mAb panel against
mAb 697, whose epitope was previously mapped (Fig. 1) (Gorny et
al., 1994), showed that all but one target the same epitope recognized
bymAb 697, or very closely overlapping V2 epitopes. The one exception
wasmAb 2297 which competed weakly with mAb 697, suggesting that
the 2297 epitope is different, but still overlaps that of the other V2
mAbs. The 697 epitope is conserved and its residues are present in a
high percentage of the sequences of the 41 psVs tested and analyzed
here (Fig. 1), as well as in the larger panel of V2 sequences previously
studied (Zolla-Pazner and Cardozo, 2010). The epitope includes two
residues contained in the highly conserved LDV/I motif, which is the
binding site for the α4β7 integrin, expressed on activated T cells
(Arthos et al., 2008). Presumably, these anti-V2 mAbs may block bind-
ing of HIV-1 to integrinwhich is supposed to be a prior step to the bind-
ing of the virus to CD4 receptor.
The ﬁnding that six of seven anti-V2 mAbs target similar epitopes
may be related to the observed preferential usage of the VH1-69 gene
by these mAbs; four of these six mAbs (or three of ﬁve if two clonalmAbs are counted as one unique mAb) are encoded by this VH
gene. Interestingly, mAb 2297, which targets a more distant epitope,
is not encoded by this gene. Preferential Ig gene usage by Abs speciﬁc
for particular epitopes is now well established (Gorny et al., 2009;
Huang et al., 2004; Scheid et al., 2009). For example, human anti-V3
mAbs which preferentially use VH5-51 and VL lambda genes target
one conserved cluster of epitopes in the crown of the V3 loop as de-
termined by crystallographic studies (Gorny et al., 2009, 2011). Sim-
ilarly, V2 mAbs encoded by the VH1-69 gene paired with VK genes
recognize a closely overlapping cluster of epitopes which have a con-
served character and near identical structures.
VH1-69 is frequently utilized by anti-CD4i and anti-gp41 mAbs
(Gorny et al., 2009; Huang et al., 2004) as well as by anti-inﬂuenza
HA mAbs (Ekiert et al., 2009; Luftig et al., 2006). It is characteristic
for these mAbs that CDR H2 displayed a particular interaction of hy-
drophobic residues at the tip of the CDR H2 domain with helical ele-
ments of the HA and gp41 antigens (Ekiert et al., 2009; Luftig et al.,
2006) or with the hydrophobic four-stranded β-sheet in the case of
anti-CD4i mAbs 412d and 17b (Huang et al., 2007; Kwong et al.,
1998). It was recently reported that the V2 domain has, also, the
four-stranded β-sheet (McLellan et al., 2011) and possibly it has a se-
lective effect on VH1-69 gene usage by 3 of 5 anti-V2 mAbs. Thus,
structural features of either the helical or beta sheet antigens contain-
ing the hydrophobic residues interact with similarly charged residues
of the CDR H2 mAbs encoded by the VH1-69 genes. The preferential
use of VH1-69 suggests that conserved epitopes in V2 best conform
to the Ab binding site encoded by this particular gene. Data of this na-
ture, elucidating conserved structures in sequence-variable epitopes,
can be useful in the development of rationally-designed immunogens
that induce cross-reactive, functional Abs (Moseri et al., 2010; Zolla-
Pazner et al., 2011b).
Final evidence that anti-V2 mAbs recognize conserved epitopes is
provided by the binding assay which showed extensive cross-
reactivity of these mAbs with various recombinant gp120s represent-
ing the sequences of clades A, AG, B and C HIV-1. The epitopes of anti-
V2 serum antibodies from RV144 vaccines have linear characteristics
and overlap with the conserved epitopes of the V2 mAbs (www.
hivvaccineenterprise.org/conference/2011/webcasting). These data
support the observation that a high titer of serum anti-V2 Abs is cor-
related with the decreased risk of HIV-1 infection in RV144 vaccines,
as only cross-reactive Abs can contribute to protection.
The mechanism of protection mediated by plasma anti-V2 Abs is un-
known but is not dependent on their neutralizing activity as no such cor-
relation was found in the RV144 vaccines (www.hivvaccineenterprise.
org/conference/2011/webcasting). The neutralizing activity of V2 mAbs
is weak, as shown here, possibly resulting from the presence of N-linked
glycosylation which may mask the V2 domain on the virus surface as
well as the V3 and CD4-binding sites. Analysis of V2 sequences revealed
that resistant pseudoviruses displayed a signiﬁcantly increased number
of residues in the V2 domainwhich is accompanied by an increased num-
ber of N-linked glycosylation sites. Other factors also contribute to the
phenomenon of resistance, as only a few Tier 2 and Tier 3 psVs, with
short V2 domains and a low number of N-linked glycosylation sites,
were not neutralized by V2 mAbs (Table 5 and Fig. 5).
The alternate hypothesis is that V2 mAbs may block virus binding
to α4β7 integrin, as expressed on activated T cells. The LDV/I motif of
integrin binding site in the V2 domain is involved in the epitope for
V2 mAbs and plasma V2 Abs from RV144 vaccines (www.
hivvaccineenterprise.org/conference/2011/webcasting) (Karasavvas
et al., 2011; Zolla-Pazner et al., 2011a) and thus they may mediate
an inhibitory function, by blocking viral access to integrin. This is sup-
ported by recently published data which showed that anti-V2 mAb
697 inhibits gp120 binding to Vγ2Vσ2 T cells which express high
levels of both α4β7 and CCR5 in the absence of CD4 expression (Li
and Pauza, 2011). Another experiment showed, also, that anti-V2
mAbs 697 and 2158 block the binding of gp120 to α4β7 integrin
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Fig. 4. Neutralization of eight Tier 1 pseudoviruses by anti-V2 mAbs using the TZM-bl cell assay. The IC50 values for these mAbs are shown in Table 4. The closed symbols indicate
three mAbs derived from one infected individual, including two clonal mAbs 1361 and 1393A. Human mAb 1418, speciﬁc for parvovirus B19, was used as a negative control.
204 M.K. Gorny et al. / Virology 427 (2012) 198–207which was expressed on the surface of retinoic-stimulated CD8 cells
(Mary A. Marovitch, unpublished data).
This additional inhibitory function of V2 mAbs was not measured
in the neutralization assay used in the study because the TZM-bl tar-
get cells do not express α4β7 integrin. Thus, in the TZM-bl cell assay,
the anti-V2 mAbs mediate neutralization by affecting the co-receptor
binding site which is formed by the stem of the V1V2, V3 and the
bridging sheet upon virus binding to the CD4 receptor (Kwong et
al., 1998; Rizzuto et al., 1998; Wu et al., 1996). Evidently, this mech-
anism of neutralization, which has a post-binding character exhibited
after the virus binds to cellular CD4, is responsible for the neutralizing
activity of anti-V2mAbs in the TZM-bl cell assay. The blocking of virus
binding to α4β7 integrin by anti-V2 Abs would precede the binding
of the virus to CD4 receptor.
In summary, the study presented in this paper is the ﬁrst to char-
acterize a panel of seven V2-speciﬁc human mAbs. We show that
these mAbs target a conserved cluster of epitopes which include the
α4β7 integrin binding site. Most of them are encoded by VH1-69
and are cross-reactive with various gp120s, suggesting that they
may recognize identical or similar epitopes. Their neutralizing activity36 38 40 42 44 46 48 50
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Fig. 5. Correlation between the length of the V2 domain and the number of potential N-
linked glycosylation sites. The potential N-linked glycosylation sites in the V2 domains
of 41 psVs were determined using the N-glycosite program from Los Alamos HIV-1 da-
tabase. Statistical analysis was determined using GraphPad Prism, version 4.01, for
Windows. Solid points (●), psVs sensitive to neutralization; open circles (○), psVs re-
sistant to neutralization.is weak and limited to neutralization-sensitive pseudotyped viruses,
suggesting that this function alone may not have contributed to the
protection which was mediated by plasma anti-V2 antibodies
detected in the RV144 vaccines. We hypothesize that the protective
function of plasma V2 Abs may depend on their ability to block
virus binding to the α4β7 integrin, and possibly, along with the neu-
tralizing activity. Given that V2-speciﬁc antibodies mediate anti-viral
functions, including potentially inhibitory activity, their elicitation
with a vaccine may contribute to protection. The elicitation of such
V2-speciﬁc Abs may be facilitated by the rational design of im-
munogens that focus the Ab response on the conserved V2 struc-
tures whose existence is strongly implied by the data presented
above.Materials and methods
Human monoclonal antibodies
Ten human mAbs, produced in our laboratory using cellular
methods as described (Gorny et al., 1991), were used; these included
seven mAbs speciﬁc for V2 (697, 830A, 1357, 1361, 1393A, 2158, and
2297) (Gorny et al., 1994, 2000; Nyambi et al., 2000; Pinter et al.,
2004) (see Table 1), one speciﬁc for the CD4 binding site (CD4bs,
mAb 654) (Nyambi et al., 1998), one speciﬁc for V3 (mAb 447-52D)
(Gorny et al., 1993), and one speciﬁc for parvovirus B19 (mAb
1418) (Gigler et al., 1999). Monoclonal Ab 2297, a new anti-V2
mAb, is described above.
This study has been reviewed and approved by the New York Uni-
versity School of Medicine Institutional Review Board.Recombinant HIV-1 proteins
Nineteen recombinant gp120s were purchased from Immune
Technology Corp. (www.immune-tech.com); gp120MN and gp120IIIB
were purchased from Immunodiagnostics, Inc. (Woburn, MA). Fusion
protein V1V2Case-A2-gp70 (V1V2-gp70) with clade B sequence and
gp70 protein were provided by Dr. Abraham Pinter (Kayman et al.,
1994) and V1V2ZM109 clade C sequence (residues 126–196) in 1FD6
scaffold was provided by Dr. Peter D. Kwong (McLellan et al., 2011),
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A standard ELISA was used to determine the binding of anti-V2
mAbs to various recombinant gp120s as previously described
(Gorny et al., 1997). Brieﬂy, gp120 proteins were coated directly
onto ELISA plates, blocked with 2% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS), and incubated with mAbs at a con-
centration 10 μg/ml or at concentrations ranging from 10 to 0.01 μg/
ml. The plates were washed, and the bound mAbs were detected by
incubation with alkaline phosphatase-conjugated goat anti-human
IgG (Fc) (Southern Biotech, Birmingham, AL). After washing, the sub-
strate p-nitrophenyl phosphate was added and the plates were read
at 410 nm.
The epitopes of the anti-V2 mAbs were determined by a competi-
tion ELISA in which unlabeled V2 mAbs competed with biotinylated
V2-speciﬁc mAb 697 for binding to V1V2-gp70, as previously de-
scribed (Gorny et al., 2002). Brieﬂy, unlabeled anti-V2 or control
mAbs at ﬁnal concentrations ranging from 10 to 0.01 μg/ml were
mixed at a 1:1 ratio with biotinylated anti-V2 mAb 697 at a concen-
tration of 0.2 μg/ml. Binding of biotinylated mAb 697 to V1V2-gp70
was detected using alkaline phosphatase-conjugated streptavidine
followed by incubation with p-nitrophenyl phosphate substrate.
Sequencing the immunoglobulin (Ig) variable fragment for heavy and
light chains
Sequencing of the Ig variable genes was performed as described
(Gorny et al., 2009). Brieﬂy, the messenger RNA was extracted from
the hybridoma cell lines and reverse transcribed into cDNA using an
oligo dT primer. Ampliﬁcation of the variable fragment of the heavy
chains (VH) was performed by PCR using gene family-speciﬁc
primers sets with a cDNA template (Gorny et al., 2009; Marks et al.,
1991). The variable domains of the light chain genes (VL) were ampli-
ﬁed from poly-C tailed cDNA by PCR using deoxyinosine-containing
anchor primer as a forward primer (5′RACE Abridged Anchor primer,
5′-GGC CAC GCG TCG ACT AGT ACG GGI IGG GII GGG IIG-3′) (Invitro-
gen) and gene-speciﬁc primer as the reverse primer, located in the
constant region of κ (5′-AAC ACT CWY YCC TGT TGA AGC TCT T-3′)
or λ (5′-CAC TGT CTT CTC CAC GGT GCT CCC TTC-3′). PCR products
for both the VH and VL genes were separately cloned into 2.1-TOPO
TA cloning vectors (Invitrogen). For each chain, 6 to 12 colonies
were screened. Plasmids with the appropriate inserts were sequenced
in both directions using the M13 primers. All sequencing reactions
were performed by Macrogen in Rockville, MD. The sequence data
were analyzed using Pregap4, BioEdit software and the International
ImMunoGene Tics (IMGT) information system (http://imgt.cines.fr).
Neutralization assay with TZM.bl target cells
The seven V2-speciﬁc human mAbs V2 and parvovirus B19-
speciﬁc mAb 1418, used as a negative control, were tested for neutral-
izing activity against 41 pseudoviruses (psVs) using the TZM-bl cell
line as target cells. The psVs carried Envs from clades A, AG, B and C
and included two psVs classiﬁed as Tier 1A, 13 from Tier 1B, 21
from Tier 2, four from Tier 3, and one classiﬁed as “chronic” (Hioe et
al., 2010; Li et al., 2005; Seaman et al., 2010). Monoclonal Abs were
tested with seven 2-fold serial dilutions starting at concentrations of
50 or 100 μg/ml. Each mAb dilution was pre-incubated with each
psV, and subsequently each mAb/psV mixture was incubated 48 h
with TZM-bl cells expressing CD4, CXCR4 and CCR5. Pseudovirus in-
fectivity was determined by measuring the luciferase activity in the
cell lysates. The reduction of infectivity was expressed as percent
neutralization by comparing the enzyme activity, as relative light
units, in the presence of mAbs versus absence of mAbs (Hioe et al.,
2010; Seaman et al., 2010).HIV-1 sequences
The sequences of the 41 psVs were aligned using Clustal X pro-
gram. Potential N-linked glycosylation sites were determined using
N-glycosite program from Los Alamos HIV-1 database.
Crystallization and structure determination of Fab 697
Fab of mAb 697 was generated by papain digestion and puriﬁed
using size exclusion chromatography (Burke et al., 2009). Well-
diffracting crystals of Fab 697 were obtained in a solution of 18% poly-
ethylene glycol 8000 and 0.1 M Tris pH 8.5 by the vapor diffusion
hanging drop method. Selected crystals were brieﬂy soaked in their
respective mother liquor with additional 20% glycerol (v/v) added
prior to mounting onto the X-ray beam. Data were collected at the
synchrotron beamline GM/CA-CAT of Advanced Photo Source, Ar-
gonne National Laboratory. The data set was processed using the
HKL2000 package (Otwinowski and Minor, 1997), and the structure
was solved by molecular replacement using MOLREP (Vagin and
Teplyakov, 1998) in the CCP4 software package with the structure
of mAbm396 (PDB: 2G75) as the starting model. Cycles of reﬁnement
were carried out using COOT (Emsley and Cowtan, 2004) and Phenix
(Adams et al., 2002). Final structural analysis was performed using
the ICM molecular modeling software package (Molsoft LLC, La Jolla,
CA) (Abagyan et al., 1994) and the ﬁgures were created using ICM
and PyMOL (DeLano, 2002).
Statistical analysis
The Student's t tests and correlation analysis were performed with
GraphPad Prism, version 4.01, for Windows (GraphPad software, San
Diego, CA).
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